Latest news with #SurgeryPartners
Business Insider
4 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), NewAmsterdam Pharma Company (NAMS) and Surgery Partners (SGRY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), NewAmsterdam Pharma Company (NAMS – Research Report) and Surgery Partners (SGRY – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. EyePoint Pharmaceuticals (EYPT) RBC Capital analyst Lisa Walter maintained a Buy rating on EyePoint Pharmaceuticals on August 6 and set a price target of $28.00. The company's shares closed last Thursday at $10.07. According to Walter is ranked 0 out of 5 stars with an average return of -15.9% and a 47.6% success rate. Walter covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Adverum Biotechnologies, and Apellis Pharmaceuticals. Currently, the analyst consensus on EyePoint Pharmaceuticals is a Strong Buy with an average price target of $26.71, representing a 147.1% upside. In a report issued on July 29, Mizuho Securities also maintained a Buy rating on the stock with a $26.00 price target. NewAmsterdam Pharma Company (NAMS) RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company on August 6 and set a price target of $39.00. The company's shares closed last Thursday at $22.96. According to Timashev is a 3-star analyst with an average return of 4.7% and a 44.1% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Edgewise Therapeutics, and Jazz Pharmaceuticals. NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $48.18, a 103.0% upside from current levels. In a report issued on July 30, Cantor Fitzgerald also maintained a Buy rating on the stock with a $42.00 price target. Surgery Partners (SGRY) In a report issued on August 6, Ben Hendrix from RBC Capital maintained a Buy rating on Surgery Partners, with a price target of $35.00. The company's shares closed last Thursday at $23.22. According to Hendrix is a 3-star analyst with an average return of 1.1% and a 48.5% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Aveanna Healthcare Holdings, and Brookdale Senior Living. Currently, the analyst consensus on Surgery Partners is a Moderate Buy with an average price target of $30.90, which is a 36.5% upside from current levels. In a report issued on August 5, TD Cowen also reiterated a Buy rating on the stock with a $28.00 price target.
Yahoo
04-08-2025
- Business
- Yahoo
Surgery Partners (SGRY) Reports Earnings Tomorrow: What To Expect
Healthcare company Surgery Partners (NASDAQ:SGRY) will be reporting results this Tuesday before market open. Here's what to expect. Surgery Partners met analysts' revenue expectations last quarter, reporting revenues of $776 million, up 8.2% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Is Surgery Partners a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Surgery Partners's revenue to grow 7.1% year on year to $816.1 million, slowing from the 14.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.14 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Surgery Partners has missed Wall Street's revenue estimates four times over the last two years. Looking at Surgery Partners's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Surgery Partners is down 3.4% during the same time and is heading into earnings with an average analyst price target of $31.08 (compared to the current share price of $21.28). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
28-07-2025
- Business
- Yahoo
Surgery Partners (SGRY) Stock Trades Up, Here Is Why
What Happened? Shares of healthcare company Surgery Partners (NASDAQ:SGRY) jumped 4.3% in the morning session after Bank of America Securities resumed coverage on the stock with a 'Buy' rating and a $28 price target. The investment firm highlighted several reasons for its positive outlook. BofA pointed to strong market tailwinds for Ambulatory Surgery Centers (ASCs), which are healthcare facilities that perform surgeries without requiring an overnight hospital stay. The analysts also noted that the stock traded at a depressed valuation compared to its historical average. BofA believed the market incorrectly penalized Surgery Partners for its joint-venture business structures. The bank had previously suspended coverage in June after the company rejected a buyout offer from private equity firm Bain Capital. After the initial pop the shares cooled down to $22.27, up 4.7% from previous close. Is now the time to buy Surgery Partners? Access our full analysis report here, it's free. What Is The Market Telling Us Surgery Partners's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 12 days ago when the stock gained 3.3% on the news that an analyst at investment firm Benchmark reiterated a "Buy" rating and a $35 price target on the company's stock. The positive sentiment from the analyst comes after a period of volatility for the surgical facilities operator. In June, the company announced it had concluded acquisition talks with private equity firm Bain Capital, opting to remain independent after determining the offer undervalued the company's potential. Despite the failed takeover, several analyst firms have maintained their positive outlooks, pointing to the company's growth prospects in the outpatient surgical care market. Surgery Partners operates a large network of ambulatory surgery centers and surgical hospitals, a sector benefiting from the ongoing shift of medical procedures out of traditional hospital settings. The reiterated Buy rating suggests confidence in the company's standalone strategy and its ability to generate value for shareholders. Surgery Partners is up 4.6% since the beginning of the year, but at $22.27 per share, it is still trading 33.9% below its 52-week high of $33.69 from August 2024. Investors who bought $1,000 worth of Surgery Partners's shares 5 years ago would now be looking at an investment worth $1,437. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Why Surgery Partners (SGRY) Stock Is Trading Up Today
What Happened? Shares of healthcare company Surgery Partners (NASDAQ:SGRY) jumped 3.3% in the morning session after an analyst at investment firm Benchmark reiterated a "Buy" rating and a $35 price target on the company's stock. The positive sentiment from the analyst comes after a period of volatility for the surgical facilities operator. In June, the company announced it had concluded acquisition talks with private equity firm Bain Capital, opting to remain independent after determining the offer undervalued the company's potential. Despite the failed takeover, several analyst firms have maintained their positive outlooks, pointing to the company's growth prospects in the outpatient surgical care market. Surgery Partners operates a large network of ambulatory surgery centers and surgical hospitals, a sector benefiting from the ongoing shift of medical procedures out of traditional hospital settings. The reiterated Buy rating suggests confidence in the company's standalone strategy and its ability to generate value for shareholders. After the initial pop the shares cooled down to $22.34, up 2.2% from previous close. Is now the time to buy Surgery Partners? Access our full analysis report here, it's free. What Is The Market Telling Us Surgery Partners's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock dropped 6.1% after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth. Trump's comments added pressure to an already sensitive market, raising concerns about political interference in monetary policy. Meanwhile, Fed Chair Jerome Powell maintained a cautious stance the previous week, highlighting the difficulty of balancing the dual mandate of steady employment and price stability amid the escalating trade tension. Investor sentiment was further dampened by the absence of constructive progress in trade negotiations, especially US-China relations which took a turn for the worse in the previous week. Overall, the outlook seemed more unclear heading into the first quarter 2025 earnings season, as a combination of hard to predict monetary policy and unresolved trade tensions weighed on business confidence. Surgery Partners is up 4.9% since the beginning of the year, but at $22.34 per share, it is still trading 33.7% below its 52-week high of $33.69 from August 2024. Investors who bought $1,000 worth of Surgery Partners's shares 5 years ago would now be looking at an investment worth $1,519. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
Surgery Partners, Inc. (SGRY): A Bull Case Theory
We came across a bullish thesis on Surgery Partners, Inc. on by Shoe. In this article, we will summarize the bulls' thesis on SGRY. Surgery Partners, Inc.'s share was trading at $22.47 as of July 14th. SGRY's trailing and forward P/E were 2.69k and 35.59 respectively according to Yahoo Finance. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Surgery Partners (SGRY), a major player in the ambulatory surgery center (ASC) space, presents a compelling special situation investment driven by a high-probability takeout by Bain Capital, which already owns 39% of the company. After a failed sale process in 2024 and a non-binding $25.75 per share offer from Bain in January 2025, the odds favor a full acquisition. Despite the stock fading from initial highs due to market volatility and macro fears, fundamentals remain intact: ASCs are a secularly advantaged model lower-cost, efficient care delivery and favorable patient outcomes. Surgery Partners, as the last pure-play public ASC, enjoys mid-teens EBITDA CAGR through a mix of organic growth and M&A, with solid strategic positioning in orthopedics and cardiology. Valuation upside is real; historical EV/EBITDA multiples for similar takeouts (UNH/SCAI, THC/USPI) support the view that Bain may need to bump its bid. Given prior trades above the bid and historical data showing bumps in ~95% of minority buyouts, a revised offer around $28 isn't far-fetched. The stock trades near technical support, and downside is cushioned at $18.5–$19.25. Jefferies and Nomura estimate Bain could still achieve >17% IRR with a takeout at $30, suggesting room for competitive interest or a strategic rerating. Recent Bain transactions worth $2B underscore its capacity to execute despite tightened credit markets. With a likely resolution in the coming weeks, possibly aligned with the unusual Monday earnings schedule, a successful deal could yield 12–23% upside. Meanwhile, Surgery Partners' ASC platform continues to benefit from favorable healthcare trends and operational improvements. Previously, we covered a on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, highlighting its debt reduction and growth in Ambulatory Care. The stock has appreciated by ~38% since, driven by execution in its ASC strategy. Shoe shares a similar thesis but emphasizes Surgery Partners' pure-play ASC positioning and potential near-term buyout by Bain Capital. Surgery Partners, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held SGRY at the end of the first quarter which was 24 in the previous quarter. While we acknowledge the potential of SGRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
